Skip to main content
a b c d e f g h i j k l m n o p q r s t u v w x y z #

Toxicology

Dihydrocodeine

Dihydrocodeine

Please contact the laboratory for guidance in therapy.

 

Units - ug/L

Diltiazem

Diltiazem

Therapeutic use of diltiazem is typically associated with concentrations between 0.05 to 0.4 mg/L. Toxicity is generally associated with concentrations > 0.8 mg/L.  (Clarke's Analysis of Drugs & Poisons, Third Edition).

Diphenhydramine

Diphenhydramine

High dose therapeutic use of diphenhydramine associated with concentrations of up to 0.3 mg/L. Toxicity associated with concentrations > 1 mg/L.  (Schulz et al. Critical Care 2012, 16:R136).

Dosulepin (Dothiepin)

Dosulepin (Dothiepin)

High dose therapeutic use of Dosulepin (Dothiepin) associated with concentrations of up to 0.4 mg/L. Toxicity associated with concentrations > 0.8 mg/L.  (Schulz et al. Critical Care 2012, 16:R136)

Drugs of Abuse Screening (DOAS)

Drugs of Abuse Screening (DOAS)

Positive results represent concentrations of drugs above the European Workplace Testing Thresholds with the exception of benzodiazepines.  We have lowered the cut off for this class of drug to 10ug/L to increase the detection of benzodiazepines.

Bromazolam, Etizolam, Flualprazolam, Flubromazolam, THC-COOH glucuronide, Buprenorphine glucuronide and Norbuprenorphine glucuronide will be qualitative only.

Drugs without a cut-off have been assigned one based on chemically similar compounds.

Fentanyl

Fentanyl

Serum fentanyl concentrations attain a range of 0.3 – 1.2 µg/L within 24 hours after application of a 25 µg/hr transdermal patch with serum levels inceasing up to 3.8 µg/L with use of a 100 µg/hr patch. (Baselt, Disposition of Toxic Drugs and Chemicals in Man, Eighth Edition, 2008). 

Fluoxetine

Fluoxetine

Therapeutic range = 120 - 500 ug/L (sum of fluoxetine and desmethylfluoxetine)

Gabapentin (Neurontin)

Gabapentin (Neurontin)

Therapeutic monitoring of gabapentin is not recommended. It may accumulate in renal failure.

Therapeutic range: 2 – 20 mg/L.

(Source: Therapeutic Drug Monitoring in Laboratory Medicine. Hallworth & Watson)

Gamma hydroxybutyrate (GHB)

Gamma hydroxybutyrate (GHB)

Gamma-hydroxybutyrate (GHB) has been employed as an anaesthetic agent but is now more widely used and abused for its sedative properties. Toxic effects (euphoria, dizziness and unconsciousness) usually occur around 15 minutes post ingestion and last on average for about 3 hours. It has been found that blood concentrations above 260 mg/L were associated with deep sleep, 156 – 260 mg/L with moderate sleep, 52 – 156 mg/L with light sleep and levels less than 52 mg/L with wakefulness.

 

Gamma hydroxybutyrate (GHB)

Gamma hydroxybutyrate (GHB)

Gamma-hydroxybutyrate (GHB) has been employed as an anaesthetic agent but is now more widely used and abused for its sedative properties. Toxic effects (euphoria, dizziness and unconsciousness) usually occur around 15 minutes post ingestion and last on average for about 3 hours. It has been found that blood concentrations above 260 mg/L were associated with deep sleep, 156 – 260 mg/L with moderate sleep, 52 – 156 mg/L with light sleep and levels less than 52 mg/L with wakefulness.

 

Imipramine and Desipramine

Imipramine and Desipramine

Therapeutic concentrations of imipramine range between 50 to 150 ug/L, with the total sum of imipramine and desipramine between 150 and 300 ug/L. 

Imipramine and Desipramine

Imipramine and Desipramine

Therapeutic concentrations of imipramine range between 50 to 150 ug/L, with the total sum of imipramine and desipramine between 150 and 300 ug/L. 

Ketamine

Ketamine

Therapeutic use of ketamine (i.v) for sedation is effective at average concentrations >0.6 mg/L. (Clarke's Analysis of Drugs & Poisons, Third Edition)

Lamotrigine (Lamictal)

Lamotrigine (Lamictal)

Therapeutic range (epilepsy): 1 - 4 mg/L

Maximum drug efficacy (bipolar disorder): 3 - 14 mg/L

Lead

Lead

Normal values: <0.24 umol/L

Desirable values in children: <0.24 umol/L

Occupational Certification Limit for women of reproductive capacity: 1.45 umol/L

Occupational Certification Limit for males (age 18+): 2.90 umol/L

INDUSTRIAL EXPOSURE

 

Repeat within 12 months

< 1.4

Repeat within 6 months

> 1.4 – 1.9

Repeat within 3 months

> 1.9 – 2.4

Repeat within 3 months

> 2.4 – 2.9

At doctors discretion but not more than 3 months

> 2.9

Please note that the normal values have been decreased as of 2018 to bring us in-line with CDC recommendations.

Levetiracetam (Keppra)

Levetiracetam (Keppra)

There is no evidence to justify monitoring of Levetiracetam other than to assess adherence, though a range of 6 – 20 mg/L has been suggested. Renal excretion means that the plasma half-life is longer in the elderly. Dose reduction is necessary at GFR < 60 mL/min/1.73 m2.

Levetiracetam (Keppra)

Levetiracetam (Keppra)

There is no evidence to justify monitoring of Levetiracetam other than to assess adherence, though a range of 6 – 20 mg/L has been suggested. Renal excretion means that the plasma half-life is longer in the elderly. Dose reduction is necessary at GFR < 60 mL/min/1.73 m2.

Lorazepam

Lorazepam

0.02 - 0.25 mg/L

<<  1 [23 4 5  >>